目的:肺炎球菌结合疫苗(PCV13、PCV15、PCV20)有效靶向最常见的致病肺炎链球菌血清型的荚膜多糖。在这个简短的交流中,作为最近结束的探索性临床试验的一部分,我们分析了接受PCV13和PCV15疫苗的健康参与者,并报告了对13种共享血清型(1,3,4,5,6A,6B,7F,9V,14,18C,19A,19F,和23F)以及对血清型3的功能性OPA反应。
方法:收集了87名随机接受PCV13或PCV15的成年参与者(18至49岁)的血清(分别为n=46或n=41),来自美国17个研究中心。在接种前和接种后1个月使用内部验证的测定分析13种共有血清型的IgG浓度和血清型3特异性OPA滴度。
结果:接种疫苗后1个月,PCV13中13种共有血清型的IgGGMC与PCV15相似。具体来说,PCV13(62.9[48.9,80.9])和PCV15(71.1[50.9,99.2])接种后1个月,血清型3OPAGMT和95%CI相似.
结论:在接受PCV13或PCV15的健康参与者中,当使用统一验证的内部检测时,在所有共享血清型之间观察到相似的血清型特异性反应。值得注意的是,这项研究的数据表明,两种疫苗诱导了类似的针对肺炎球菌血清型3的功能性抗体应答。
Pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) effectively target the capsular polysaccharides of the most common disease-causing Streptococcus pneumoniae serotypes. In this short communication, we analyzed healthy participants who received PCV13 and PCV15 vaccines as part of a recently concluded exploratory clinical trial and report antibody responses to the 13 shared serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as well as functional OPA responses to serotype 3.
Sera from 87 adult participants (18 through 49 years of age) randomized to receive either PCV13 or PCV15 were collected (n = 46 or n = 41, respectively), from 17 study centers in the US. IgG concentrations of the 13 shared serotypes and serotype 3-specific OPA titers were analyzed before and 1 month after vaccination using internally validated assays.
At 1 month after vaccination, IgG GMCs of the 13 shared serotypes in PCV13 were similar to those for PCV15. Specifically, serotype 3 OPA GMTs and 95% CIs were similar 1 month after vaccination for PCV13 (62.9 [48.9, 80.9]) and PCV15 (71.1 [50.9, 99.2]).
In healthy participants who received either PCV13 or PCV15, similar serotype-specific responses were observed between all shared serotypes when a uniform validated internal assay was used. Of note, data from this study suggest that both vaccines induce similar functional antibody responses against pneumococcal serotype 3.